EC FP6 funding directed at device industry:
This article was originally published in Clinica
Executive Summary
Imaging, radiotherapy, clinical trials for breast cancer and leukaemia, and the link between genomics and cancer have been selected by the European Commission among the first group of 19 projects to receive some E100m ($116m) of funding in the context of its Sixth Framework Programme (FP6 2002-2006). The projects will also aim to create bio-banks and cancer registers. A key focus, the Commission says, will be to "quickly turn the advances in cancer research into practical and meaningful early stage diagnoses and therapies for patients". The projects respond to the challenge of creating a European Research Area, according to the Commission, and were chosen to reinforce European excellence and promote research in the fight against cancer.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.